US FDA allows closed J&J plant to resume production

Thursday, 29. July 2021 23:50

Biopharmaceutical company Emergent BioSolutions Inc. announced on Thursday the United States Food and Drug Administration (FDA) has given it permission to reopen its plant in Baltimore that the institution put under probe over the alleged mishandling in producing components for Johnson & and Johnson's (J&J) vaccine against COVID-19.

"We have fallen short of those lofty ambitions over the past few months, but resumption of manufacturing is a key milestone, and we are grateful for the opportunity to help bring this global pandemic to an end," Emergent Chief Executive Officer (CEO) Robert Kramer stated.

The FDA put the production at the plant in Baltimore on hold in April following the discovery certain doses of J&J's jabs have been contaminated with ingredients used for the manufacturing of AstraZeneca PLC and Oxford University's treatment. The agency later opened the probe into the case but still decided to release around 10 million doses that Emergent produced.

Related Links: Johnson & Johnson
Breaking the News / JR